The oncolytic adenovirus Ad-TD-nsIL12 in primary or progressive pediatric IDH wild-type diffuse intrinsic pontine glioma results of two phase I clinical trials



Summary

Two Phase I clinical trials evaluated the safety and efficacy of Ad-TD-nsIL12, an oncolytic adenovirus, in children with primary or progressive IDH wild-type diffuse intrinsic pontine glioma (DIPG), a deadly brain tumor. The studies involved direct injection of the virus into the tumor. Preliminary results focused on safety and tolerability. While details on efficacy are limited, the trials aimed to determine the optimal dose and assess the virus’s ability to induce an immune response against the tumor. These trials represent an attempt to improve outcomes for children with DIPG by harnessing the tumor-killing and immune-stimulating properties of oncolytic viruses.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!